These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 30499149)
1. Cyclohexanone curcumin analogs inhibit the progression of castration-resistant prostate cancer in vitro and in vivo. Mapoung S; Suzuki S; Fuji S; Naiki-Ito A; Kato H; Yodkeeree S; Ovatlarnporn C; Takahashi S; Limtrakul Dejkriengkraikul P Cancer Sci; 2019 Feb; 110(2):596-607. PubMed ID: 30499149 [TBL] [Abstract][Full Text] [Related]
2. Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor In Vitro and In Vivo. Mapoung S; Suzuki S; Fuji S; Naiki-Ito A; Kato H; Yodkeeree S; Sakorn N; Ovatlarnporn C; Takahashi S; Limtrakul Dejkriengkraikul P Molecules; 2020 Jun; 25(12):. PubMed ID: 32545675 [TBL] [Abstract][Full Text] [Related]
3. Matrine suppresses invasion of castration-resistant prostate cancer cells by downregulating MMP-2/9 via NF-κB signaling pathway. Huang H; Du T; Xu G; Lai Y; Fan X; Chen X; Li W; Yue F; Li Q; Liu L; Li K Int J Oncol; 2017 Feb; 50(2):640-648. PubMed ID: 28000853 [TBL] [Abstract][Full Text] [Related]
4. Characterization of a novel p110β-specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells. He C; Duan S; Dong L; Wang Y; Hu Q; Liu C; Forrest ML; Holzbeierlein JM; Han S; Li B Prostate; 2017 Aug; 77(11):1187-1198. PubMed ID: 28631436 [TBL] [Abstract][Full Text] [Related]
5. NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer. Chen Z; Jiang Q; Zhu P; Chen Y; Xie X; Du Z; Jiang L; Tang W Prostate; 2019 Jan; 79(1):44-53. PubMed ID: 30178500 [TBL] [Abstract][Full Text] [Related]
6. PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells. Kang M; Lee KH; Lee HS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C Prostate; 2016 Feb; 76(3):273-85. PubMed ID: 26499308 [TBL] [Abstract][Full Text] [Related]
7. Heterocyclic cyclohexanone monocarbonyl analogs of curcumin can inhibit the activity of ATP-binding cassette transporters in cancer multidrug resistance. Revalde JL; Li Y; Hawkins BC; Rosengren RJ; Paxton JW Biochem Pharmacol; 2015 Feb; 93(3):305-17. PubMed ID: 25543853 [TBL] [Abstract][Full Text] [Related]
8. A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells. Sasaki H; Klotz LH; Sugar LM; Kiss A; Venkateswaran V Biochem Biophys Res Commun; 2015 Aug; 464(3):848-54. PubMed ID: 26182875 [TBL] [Abstract][Full Text] [Related]
9. A natural molecule, urolithin A, downregulates androgen receptor activation and suppresses growth of prostate cancer. Dahiya NR; Chandrasekaran B; Kolluru V; Ankem M; Damodaran C; Vadhanam MV Mol Carcinog; 2018 Oct; 57(10):1332-1341. PubMed ID: 30069922 [TBL] [Abstract][Full Text] [Related]
10. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer. Thamilselvan V; Menon M; Thamilselvan S Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552 [TBL] [Abstract][Full Text] [Related]
11. Chemosensitizing effects of synthetic curcumin analogs on human multi-drug resistance leukemic cells. Mapoung S; Pitchakarn P; Yodkeeree S; Ovatlarnporn C; Sakorn N; Limtrakul P Chem Biol Interact; 2016 Jan; 244():140-8. PubMed ID: 26689174 [TBL] [Abstract][Full Text] [Related]
12. Sea cucumber extract TBL-12 inhibits the proliferation, migration, and invasion of human prostate cancer cells through the p38 mitogen-activated protein kinase and intrinsic caspase apoptosis pathway. Yuan L; Huang X; Zhou K; Zhu X; Huang B; Qiu S; Cao K; Xu L Prostate; 2019 Jun; 79(8):826-839. PubMed ID: 30889629 [TBL] [Abstract][Full Text] [Related]
13. Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer. Zhou X; Zou L; Chen W; Yang T; Luo J; Wu K; Shu F; Tan X; Yang Y; Cen S; Li C; Mao X Pharmacol Res; 2021 Feb; 164():105305. PubMed ID: 33197601 [TBL] [Abstract][Full Text] [Related]
14. Tubulin-Binding 3,5-Bis(styryl)pyrazoles as Lead Compounds for the Treatment of Castration-Resistant Prostate Cancer. Liao VWY; Kumari A; Narlawar R; Vignarajan S; Hibbs DE; Panda D; Groundwater PW Mol Pharmacol; 2020 Jun; 97(6):409-422. PubMed ID: 32241960 [TBL] [Abstract][Full Text] [Related]
15. Anticancer potential of novel curcumin analogs towards castrate-resistant prostate cancer. Chen S; Nimick M; Cridge AG; Hawkins BC; Rosengren RJ Int J Oncol; 2018 Feb; 52(2):579-588. PubMed ID: 29207190 [TBL] [Abstract][Full Text] [Related]
16. Androgen receptor (AR) degradation enhancer ASC-J9 Cheng MA; Chou FJ; Wang K; Yang R; Ding J; Zhang Q; Li G; Yeh S; Xu D; Chang C Cancer Lett; 2018 Mar; 417():182-191. PubMed ID: 29203251 [TBL] [Abstract][Full Text] [Related]
17. ABCB1-mediated docetaxel resistance reversed by erastin in prostate cancer. Chen F; Wu S; Kuang N; Zeng Y; Li M; Xu C FEBS J; 2024 Jul; 291(14):3249-3266. PubMed ID: 38712529 [TBL] [Abstract][Full Text] [Related]
18. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition. Selvendiran K; Ahmed S; Dayton A; Kuppusamy ML; Rivera BK; Kálai T; Hideg K; Kuppusamy P Cancer Biol Ther; 2011 Nov; 12(9):837-45. PubMed ID: 21885917 [TBL] [Abstract][Full Text] [Related]
19. Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer. Zhang X; He Z; Xiang L; Li L; Zhang H; Lin F; Cao H Drug Des Devel Ther; 2019; 13():1357-1372. PubMed ID: 31118572 [No Abstract] [Full Text] [Related]
20. Curcumin analog B14 has high bioavailability and enhances the effect of anti-breast cancer cells in vitro and in vivo. Shen H; Shen J; Pan H; Xu L; Sheng H; Liu B; Yao M Cancer Sci; 2021 Feb; 112(2):815-827. PubMed ID: 33316116 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]